Company news
Altimmune, Inc. news in 2021
Altimmune, Inc.'s news releases, calls and decks from 2021, newest first.
Altimmune Appoints Richard Eisenstadt as Chief Financial Officer
December 12, 2021
Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
November 8, 2021
Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021
November 2, 2021
Altimmune Announces Initiation of 12-week Phase 1b Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease
October 3, 2021
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
September 27, 2021
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
September 26, 2021
Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
August 9, 2021
Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021
August 3, 2021
Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial
June 28, 2021
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
June 15, 2021
Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update
May 16, 2021
Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021
May 10, 2021
Altimmune Announces New Preclinical Data for AdCOVID™ Demonstrating Sterilizing Immunity After a Single Intranasal Dose
May 9, 2021
Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™
March 31, 2021
Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID™ Vaccine Candidate
March 21, 2021
Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza
March 11, 2021
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
February 24, 2021
Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update
February 24, 2021
Altimmune To Announce Year End 2020 Financial Results on February 25, 2021
February 21, 2021
Altimmune Announces FDA Clearance of AdCOVID™ IND Application
February 16, 2021
Calls in 2021
Decks in 2021
- Q1 2021 Earnings Presentation
Earnings · 13 slides · May 17, 2021